An observational study in Intracranial Aneurysm, sponsored by Medtronic Neurovascular Clinical Affairs. Active, not recruiting at 16 sites in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.
Sponsored by Medtronic Neurovascular Clinical Affairs (part of Medtronic) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Intracranial Aneurysm by Medtronic — 4 open to participants now, 5 under way, none of them phase 3. Intracranial Aneurysm · Medtronic.
Among the 16 studies in Intracranial Aneurysm by Medtronic, this one is the 4th largest by enrollment of the 10 observational ones that give a count, is the only one that started in 2021, is one of 10 observational ones, and was the 15th registered.
418 studies on the registry are indexed under Intracranial Aneurysm; 118 are open to participants now.
Browse Intracranial Aneurysm studies →4 of the 16 studies in Intracranial Aneurysm by Medtronic are open now, in 12 countries. Recruiting first, the newest first:
Medtronic Neurovascular Clinical Affairs · Sites in United States
Ages 22+
Medtronic Neurovascular Clinical Affairs · Sites in United States
Ages 18–75
Medtronic Neurovascular Clinical Affairs · Sites in Argentina, Australia, Austria and 21 more countries
Ages 18+
Medtronic · Sites in United States, Argentina, Australia and 38 more countries
By country, each count listing its studies:
Of the 83 Intracranial Aneurysm studies recruiting now, 49 (59%) set no upper age limit and 15 (18%) stop at 75 or younger; 16 take children under 18; 6 take healthy volunteers.
This study: 22 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2021.
This study's enrollment of 246 is above the median of 200 across 191 observational studies indexed under Intracranial Aneurysm.
Median enrollment 67 across the 6 interventional studies, 203 across the 10 observational. Of the 9 that completed or were terminated, 5 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Medtronic Neurovascular Clinical Affairs, one of the names counted as Medtronic. Under that name alone:
Medtronic Neurovascular Clinical Affairs is the lead sponsor of 32 studies on the registry; 4 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
2 of the studies in Intracranial Aneurysm by Medtronic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05071963Medtronic Neurovascular Clinical AffairsINSPIRE Pipeline™ Shield Post Approval Study | 2027-01 |
| NCT02998229Medtronic Neurovascular Clinical AffairsThe Artisse™ Intrasaccular Device is Indicated for the Treatment of Wide-neck Bifurcating Intracranial Aneurysms (IAs). | 2027-08 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies in Intracranial Aneurysm by Medtronic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the Pipeline™ Flex Embolization Device with Shield Technology™ Post Approval Study (PAS) ("Pipeline™ Shield PAS") is to collect on-label use data in patients undergoing treatment for intracranial aneurysms (IA) using the Pipeline™ Flex Embolization Device with Shield Technology™ ("Pipeline™ Shield Device") in a real-world post approval setting within the United States.
The INSPIRE Pipeline™ Shield Post Approval Study is an observational, prospective, multi-center, single-arm registry to collect on-label use data in patients undergoing treatment for intracranial aneurysms using the Pipeline™ Flex Embolization Device with Shield Technology™ according to the intended use.
The primary objective of this study is to evaluate the on-label use of the Pipeline™ Shield Device in patients undergoing treatment for intracranial aneurysms per institutional routine clinical care in a real-world post approval study setting in the U.S.
This study is conducted under the Product Surveillance Registry (NCT01524276) and is a sub-study to the therapy specific Neurovascular Product Surveillance Registry (NCT02988128).
Patients requiring treatment for intracranial aneurysms with the market approved Pipeline™ Flex Embolization Device with Shield Technology™ device are eligible for the registry
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Embolization of aneurysms using the Pipeline™ Flex Embolization Device with Shield Technology™
Incidence of the composite outcome (Occlusion of the target aneurysm, Significant parent artery stenosis, Retreatment of the target aneurysm) at 1 year post-procedure.
Incidence at 1-year post-procedure of complete occlusion of the target aneurysm, significant parent artery stenosis ≤ 50%, and no retreatment of the target aneurysm.
Time frame: 1 year
Plan to share: No — No individual participant data will be available
No publications or documents are linked to this record.
Started Dec 2021 (actual). Primary completion is estimated for Jan 2027, 61 months after the start.
Of 105 observational studies under Intracranial Aneurysm, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 145. This study's planned 61 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medtronic Neurovascular Clinical Affairs →